Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE)
NCT06475742Phase 3Enrolling by invitation
- Sponsor
- Viatris
- Start
- Jul 2024
- Primary completion
- Sep 2032
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of cenerimod in systemic lupus erythematosus (SLE), sponsored by Viatris. Started Jul 2024; status: enrolling by invitation.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06475742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475742.